+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia-Pacific Oncology Molecular Diagnostics Market by Application, End User and Country: Regional Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5125522
  • Report
  • May 2020
  • Region: Asia Pacific
  • 158 Pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • Abbott Laboratories
  • BioMérieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Illumina
  • Novartis AG

The Asia Pacific oncology molecular diagnostics market was valued at $381.84 million in 2018 and is projected to reach $732.05 million by 2026, registering a CAGR of 9.0% from 2019 to 2026.





Molecular diagnostics is a set of cumulative techniques used for analyzing biological markers at molecular level such as genome and proteome. It is used for diagnosis and prediction of various infectious diseases, cancers, and other genetic disorders. Advancements in molecular diagnostics, including increased precision, faster turnarounds, and reduced costs act as key drivers for better genetic information.

The market is segmented on the basis of application, end user, and country. By application, it is categorized into lung, colorectal, breast, hematological, and others. By End User, it is segmented into hospitals, reference laboratories, and others (research institutes and academics). The hospitals segment was the highest contributor to the market, with $184.27 million in 2018, and is estimated to reach $354.46 million by 2026, at a CAGR of 9.0% during the forecast period.

Country wise, the market is divided into Australia, Vietnam, the Philippines, Thailand, and rest of Asia-Pacific. The oncology molecular diagnostics market growth, by country, is attributed to higher adoption and acceptance of personalized medicine, upgradation of healthcare infrastructure, and higher investments for R&D. Further, the market growth is attributed to increase in number of patients suffering from cancer in Asia-Pacific.

The key players profiled in this report include F. Hoffmann-La Roche AG, BioMérieux SA, Abbott Laboratories, Qiagen N.V., Sysmex, Danaher Corporation, S.A., Danaher, and Siemens Healthcare GmbH.

KEY BENEFITS FOR STAKEHOLDERS


  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the Asia-Pacific oncology molecular diagnostics market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Application


  • Breast cancer

By Technology


  • PCR

By Type


  • Instruments
  • Reagents
  • Software & Services
  • NGS
  • By Type
  • Instruments
  • Reagents
  • Flow Cytometry
  • FISH
  • CISH
  • NGS
  • Hematological cancer
  • Colorectal cancer
  • Lung cancer
  • Others

By End User


  • Hospitals
  • Reference Laboratories
  • Others

By Country


  • Australia
  • Thailand
  • The Philippines
  • Vietnam
  • Rest of Asia-Pacific 

KEY MARKET PLAYERS


  • F. Hoffmann-La Roche AG
  • BioMérieux SA
  • Abbott Laboratories
  • Qiagen N.V.
  • Sysmex Corporation
  • Danaher Corporation, S.A.
  • Siemens Healthcare GmbH.
  • DiaSorin
  • Illumina
  • Agilent Technologies
Frequently Asked Questions about the Asian Pacific Oncology Molecular Diagnostics Market

What is the estimated value of the Asian Pacific Oncology Molecular Diagnostics Market?

The Asian Pacific Oncology Molecular Diagnostics Market was estimated to be valued at $381.8 million in 2018.

What is the growth rate of the Asian Pacific Oncology Molecular Diagnostics Market?

The growth rate of the Asian Pacific Oncology Molecular Diagnostics Market is 8.5%, with an estimated value of $732.1 million by 2026.

What is the forecasted size of the Asian Pacific Oncology Molecular Diagnostics Market?

The Asian Pacific Oncology Molecular Diagnostics Market is estimated to be worth $732.1 million by 2026.

Who are the key companies in the Asian Pacific Oncology Molecular Diagnostics Market?

Key companies in the Asian Pacific Oncology Molecular Diagnostics Market include F. Hoffmann, La Roche AG, BioMérieux SA, Abbott Laboratories, Qiagen N.V., Illumina, Danaher Corporation, S.A. and Siemens Healthcare.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • BioMérieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Illumina
  • Novartis AG

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools & Models
Chapter 2: Executive Summary
2.1. CXO Perspective
Chapter 3: Market Overview
3.1. Key Findings
3.1.1. Top Investment Pockets
3.1.2. Top Player Positioning, 2018
3.1.3. Key Forces Shaping the Asia-Pacific Oncology Molecular Diagnostics Market
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Rise in Prevalence of Various Types of Cancersw
3.2.1.2. Growth in Funding by Governmentsw
3.2.1.3. Growth in Biomarker Identification
3.2.2. Restraints
3.2.2.1. Lack of Skilled Professionals
3.2.2.2. Stringent Regulatory Requirements for Product Approvals
3.2.3. Opportunities
3.2.3.1. Advancements in Genomics and Proteomics
3.3. Regulatory Guidelines for Molecular Diagnostics
3.4. Recommended Guidelines for Oncology Molecular Diagnostics Tests
3.5. Insights on Clinical Flow Cytometry Panel
3.6. Pricing Ranges for Technology
Chapter 4: Asia-Pacific Oncology Molecular Diagnostics Market, by Application
4.1. Overview
4.1.1. Asia-Pacific Oncology Molecular Diagnostics Market, by Application
4.2. Colorectal Cancer
4.2.1. Asia-Pacific Oncology Molecular Diagnostics Market, by Technology for Colorectal Cancer
4.2.2. Colorectal Oncology Molecular Diagnostics Market, by Pcr-Based Technology
4.2.3. Colorectal Oncology Molecular Diagnostics Market, by Ngs Based Technology
4.2.4. Colorectal Oncology Molecular Diagnostics Market, by Flow Cytometry Based Technology
4.2.5. Colorectal Oncology Molecular Diagnostics Market, by Fish Based Technology
4.2.6. Colorectal Oncology Molecular Diagnostics Market, by Cish Based Technology
4.2.7. Colorectal Oncology Molecular Diagnostics Market, by Others Based Technology
4.3. Hematological Cancer
4.3.1. Market Size and Forecast
4.3.2. Hematological Oncology Molecular Diagnostics Market, by Pcr-Based Technology
4.3.3. Hematological Oncology Molecular Diagnostics Market, by Ngs Based Technology
4.3.4. Hematological Oncology Molecular Diagnostics Market, by Flow Cytometry Based Technology
4.3.5. Hematological Oncology Molecular Diagnostics Market, by Fish Based Technology
4.3.6. Hematological Oncology Molecular Diagnostics Market, by Cish Based Technology
4.3.7. Hematological Oncology Molecular Diagnostics Market, by Others Based Technology
4.4. Breast Cancer
4.4.1. Market Size and Forecast
4.4.2. Breast Oncology Molecular Diagnostics Market, by Pcr-Based Technology
4.4.3. Breast Oncology Molecular Diagnostics Market, by Ngs Based Technology
4.4.4. Breast Oncology Molecular Diagnostics Market, by Flow Cytometry Based Technology
4.4.5. Breast Oncology Molecular Diagnostics Market, by Fish Based Technology
4.4.6. Breast Oncology Molecular Diagnostics Market, by Cish Based Technology
4.4.7. Breast Oncology Molecular Diagnostics Market, by Others Based Technology
4.5. Lung Cancer
4.5.1. Market Size and Forecast
4.5.2. Lung Oncology Molecular Diagnostics Market, by Pcr-Based Technology
4.5.3. Lung Oncology Molecular Diagnostics Market, by Ngs Based Technology
4.5.4. Lung Oncology Molecular Diagnostics Market, by Flow Cytometry Based Technology
4.5.5. Lung Oncology Molecular Diagnostics Market, by Fish Based Technology
4.5.6. Lung Oncology Molecular Diagnostics Market, by Cish Based Technology
4.5.7. Lung Oncology Molecular Diagnostics Market, by Others Based Technology
4.6. Other Cancers
4.6.1. Market Size and Forecast
4.6.2. Others Oncology Molecular Diagnostics Market, by Pcr-Based Technology
4.6.3. Others Oncology Molecular Diagnostics Market, by Ngs Based Technology
4.6.4. Others Oncology Molecular Diagnostics Market, by Flow Cytometry Based Technology
4.6.5. Others Oncology Molecular Diagnostics Market, by Fish Based Technology
4.6.6. Others Oncology Molecular Diagnostics Market, by Cish Based Technology
4.6.7. Others Oncology Molecular Diagnostics Market, by Others Based Technology
Chapter 5: Asia-Pacific Oncology Molecular Diagnostics Market, by End-user
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Hospitals
5.2.1. Market Size and Forecast
5.3. Reference Laboratories
5.3.1. Market Size and Forecast
5.4. Others
5.4.1. Market Size and Forecast
Chapter 6: Asia-Pacific Oncology Molecular Diagnostics Market, by Country
6.1. Overview
6.1.1. Key Market Trends and Opportunities
6.1.2. Asia-Pacific Oncology Molecular Diagnostics Market, by Country
6.2. Australia
6.2.1. Australia Oncology Molecular Diagnostics Market, by Application
6.2.2. Australia Oncology Molecular Diagnostics Market, by End-user
6.2.3. Market Share Analysis of Top Players, 2018
6.3. Vietnam
6.3.1. Vietnam Oncology Molecular Diagnostics Market, by Application
6.3.2. Vietnam Oncology Molecular Diagnostics Market, by End-user
6.3.3. Market Share Analysis of Top Players, 2018
6.4. Thailand
6.4.1. Thailand Oncology Molecular Diagnostics Market, by Application
6.4.2. Thailand Oncology Molecular Diagnostics Market, by End-user
6.4.3. Market Share Analysis of Top Players, 2018
6.5. Philippines
6.5.1. Philippines Oncology Molecular Diagnostics Market, by Application
6.5.2. Philippines Oncology Molecular Diagnostics Market, by End-user
6.5.3. Market Share Analysis of Top Players, 2018
6.6. Rest of Asia-Pacific
6.6.1. Rest of Asia-Pacific Oncology Molecular Diagnostics Market, by Application
6.6.2. Rest of Asia-Pacific Oncology Molecular Diagnostics Market, by End-user
Chapter 7: Company Profiles
7.1. Abbott Laboratories
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Biomérieux Sa
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Product Portfolio
7.2.4. Business Performance
7.2.5. Key Strategic Moves and Developments
7.3. Qiagen N. V.
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.3.6. Key Strategic Moves and Developments
7.4. F. Hoffmann-La Roche Ltd
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves and Developments
7.5. Siemens Healthineers
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.6. Danaher (Cepheid)
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.6.6. Key Strategic Moves and Developments
7.7. Diasorin Spa
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Product Portfolio
7.7.4. Business Performance
7.7.5. Key Strategic Moves and Developments
7.8. Illumina Inc.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.8.6. Key Strategic Moves and Developments
7.9. Agilent Technologies Inc.
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.9.6. Key Strategic Moves and Developments
7.10. Sysmex Corporation
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
7.10.6. Key Strategic Moves and Developments
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • BioMérieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Illumina
  • Novartis AG
According to the report titled, 'Asia-Pacific Oncology Molecular Diagnostics Market by Application, End user, and Country: Regional Opportunity Analysis and Industry Forecast, 2019-2026', the Asia-Pacific oncology molecular diagnostics market was valued at $318.84 million in 2018 and is projected to reach $732 million by 2026, growing at a CAGR of 9% from 2019 to 2026.

The hospitals segment was the highest contributor to the market, and is estimated to reach $354.46 million by 2026, at a CAGR of 9.0% during the forecast period.

Molecular diagnosis is a method used to identify a disease at the molecular level, such as proteins, DNA, and RNA, in a tissue or fluid. Various tools are used to detect specific sequences of DNA or RNA that may or may not be associated with the disease such as single nucleotide polymorphism (SNP), deletions, rearrangements, and insertions, which are used for diagnosis and prediction of various infectious diseases, cancer, and other genetic disorders.

Factors such as increase in prevalence of various types of cancer, an increase in awareness and acceptance of personalized medicines, and growth in biomarker identification drive the growth of this market. Whereas, lack of skilled professional and stringent regulatory requirements for approval of new molecular diagnostic techniques restrain market growth.

Growth in funding by governments and numerous organizations for Research & Development (R&D) activities in molecular diagnostics is anticipated to drive the demand for the molecular diagnostics market. In addition, funding plays an important role in product development, product expansion, and product enhancement process.

Among application, lung cancer segment held a dominant portion in the market, accounting for about two-thirds share of the Asia-Pacific Oncology Molecular Diagnostics market. This is attributed to rise in incident rate of lung cancer cases with sub-standard prediction of diagnosis and elevated mortality rate, in addition need for timely diagnosis of cancer will drive the overall market during the forecast period. Lung cancer is the most common cause of cancer-related deaths in Asia. It is categorized by cell type such as non-small cell lung cancer (NSCLC) and small cell lung cancer. NSCLC is responsible for around 85% of cases and, as a result, is the primary focus in the development of personalized therapies.

Among end user, the hospital segment is expected to grow at a significant CAGR of 9% during the forecast period. Most diagnostic tests are carried out in hospital laboratories, hence molecular diagnostic products are often used in hospitals. The presence of molecular diagnostics instruments in hospitals give total cure to patients by quick analysis and diagnosis of cancer to start required treatment at the right time. Therefore, easy accessibility of molecular diagnostics at hospitals majorly drive the molecular diagnostics market in hospitals.

Key Findings of the Study:

Lung cancer is expected to be one of the most lucrative segments, registering a CAGR of 9.5% during the forecast period.
Australia dominated the Asia-Pacific oncology molecular diagnostics market, and is projected to retain this trend throughout the forecast period.
Rest of Asia-Pacific is expected to exhibit the highest growth in the Asia-Pacific oncology molecular diagnostics market, registering a CAGR of 9.3% during the forecast period.

The report provides a comprehensive analysis of the key players operating in the Asia-Pacific Oncology Molecular Diagnostics market, namely F. Hoffmann-La Roche AG, BioMérieux SA, Abbott Laboratories, Qiagen N.V., Illumina, Danaher Corporation, S.A., Novartis AG, and Siemens Healthcare.
Note: Product cover images may vary from those shown
  • F. Hoffmann-La Roche AG
  • BioMérieux SA
  • Abbott Laboratories
  • Qiagen N.V.
  • Illumina
  • Danaher Corporation
  • S.A.
  • Novartis AG
  • Siemens Healthcare
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...